Alpha-2 macroglobulin is genetically associated with Alzheimer disease

Alpha-2-macroglobulin (α-2M; encoded by the gene A2M) is a serum pan-protease inhibitor that has been implicated in Alzheimer disease (AD) based on its ability to mediate the clearance and degradation of Aß, the major component of ß-amyloid deposits. Analysis of a deletion in the A2M gene at the 5' splice site of 'exon II' of the bait region (exon 18) revealed that inheritance of the deletion (A2M-2 ) confers increased risk for AD (Mantel-Haenzel odds ratio = 3.56, P = 0.001). The sibship disequilibrium test (SDT) also revealed a significant association between A2M and AD (P = 0.00009). These values were comparable to those obtained for the APOE-ε4 allele in the same sample, but in contrast to APOE-ε4, A2M-2 did not affect age of onset. The observed association of A2M with AD did not appear to account for the previously published linkage of AD to chromosome 12, which we were unable to confirm in this sample. A2M, LRP1 (encoding the α-2M receptor) and the genes for two other LRP ligands, APOE and APP (encoding the amyloid ß-protein precursor), have now all been genetically linked to AD, suggesting that these proteins may participate in a common neuropathogenic pathway leading to AD.

[1]  S. Paul,et al.  Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. , 1997, Nature genetics.

[2]  Margaret A. Pericak-Vance,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease , 1997 .

[3]  O. Khorkova,et al.  α2-macroglobulin associates with β-amyloid peptide and prevents fibril formation , 1998 .

[4]  S. Vandenberg,et al.  Expression of α2‐macroglobulin receptor/low density lipoprotein receptor‐related protein is increased in reactive and neoplastic glial cells , 1994, FEBS letters.

[5]  B. Hyman,et al.  Confirmation of an association between a polymorphism in exon 3 of the low‐density lipoprotein receptor‐related protein gene and Alzheimer's disease , 1998, Neurology.

[6]  Jurg Ott,et al.  Handbook of Human Genetic Linkage , 1994 .

[7]  Carl Wood,et al.  Current Status and Future Prospects , 1984 .

[8]  D. Selkoe,et al.  Degradation of Amyloid -Protein by a Serine Protease--Macroglobulin Complex (*) , 1996, The Journal of Biological Chemistry.

[9]  L. Thal,et al.  late-onset Alzheimer’s disease , 2007 .

[10]  D. Holtzman,et al.  α2‐Macroglobulin Complexes with and Mediates the Endocytosis of β‐Amyloid Peptide via Cell Surface Low‐Density Lipoprotein Receptor‐Related Protein , 1997 .

[11]  J. Hardy,et al.  Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. , 1997, Human molecular genetics.

[12]  D. Blacker,et al.  The genetics of Alzheimer disease: current status and future prospects. , 1998, Archives of neurology.

[13]  L Kruglyak,et al.  Parametric and nonparametric linkage analysis: a unified multipoint approach. , 1996, American journal of human genetics.

[14]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[15]  W. Borth.  α2“Macroglobulin, a multifunctional binding protein with targeting characteristics , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  B. Hyman,et al.  Multiple, diverse senile plaque–associated proteins are ligands of an apolipoprotein e receptor, the α2‐macroglobulin receptor/low‐density‐lipoprotein receptor—related protein , 1995, Annals of neurology.

[17]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[18]  R. Dodel,et al.  α2‐Macroglobulin as a β‐Amyloid Peptide‐Binding Plasma Protein , 1997 .

[19]  B. Hyman,et al.  LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted β-amyloid precursor protein and mediates its degradation , 1995, Cell.

[20]  J. Growdon,et al.  Transmission and age-at-onset patterns in familial Alzheimer??s disease: evidence for heterogeneity , 1991 .

[21]  K. Welsh-Bohmer,et al.  APOE genotype predicts when — not whether — one is predisposed to develop Alzheimer disease , 1998, Nature Genetics.

[22]  Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. , 1996, The Journal of biological chemistry.

[23]  J. Haines,et al.  Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. , 1997, JAMA.

[24]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[25]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Strickland,et al.  Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. , 1990, The Journal of biological chemistry.

[27]  P. Marynen,et al.  A deletion polymorphism in the human alpha-2-macroglobulin (A2M) gene. , 1991, Nucleic acids research.

[28]  J. Haines,et al.  ApoE-4 and Age at Onset of Alzheimer's Disease , 1997, Neurology.

[29]  M. Owen,et al.  Genetic studies on chromosome 12 in late-onset Alzheimer disease. , 1998, JAMA.

[30]  W. Ewens,et al.  A sibship test for linkage in the presence of association: the sib transmission/disequilibrium test. , 1998, American journal of human genetics.

[31]  K. Montgomery,et al.  A second-generation YAC contig map of human chromosome 12. , 1995, Nature.

[32]  F. Pasquier,et al.  A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. , 1998, Human molecular genetics.

[33]  M. Albert,et al.  Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative. , 1994, Archives of neurology.

[34]  J. Growdon,et al.  Transmission and age‐at‐onset patterns in familial Alzheimer's disease , 1990, Neurology.

[35]  S. Paul,et al.  α2‐Macroglobulin Attenuates β‐Amyloid Peptide 1–40 Fibril Formation and Associated Neurotoxicity of Cultured Fetal Rat Cortical Neurons , 1998 .

[36]  S. Paul,et al.  Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition , 1997, Nature Genetics.

[37]  J. Morris,et al.  A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia , 1998, Nature Genetics.

[38]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[39]  S. Paul,et al.  Inhibition of α2-macroglobulin/proteinase-mediated degradation of amyloid β peptide by apolipoprotein E and α1-antichymotrypsin; Evidence that the α2-macroglobulin/proteinase complex mediates degradation of the Aβ peptide , 1996 .